Författare: Åkesson Eva, Fredrikson Sten

Titel: ABC om multipel skleros (serie: Medicinens ABC) 2004 nr 32 sid 2489-93

Läs/ladda hem artikeln:
Översikt
Fullständig referenslista
Artikeln i pdf-format
Sid 2489
Sid 2490
Sid 2491
Sid 2492
Sid 2493
Om Läkartidningens fulltext på Internet
Ämnesord:
Multipel skleros























Sök liknande artiklar

Referenser:
1 Info från Läkemedelsverket 1:2000 (Behandling av multipel skleros - rekommendationer) samt 3:2001 (Kompletterande behandlingsrekommendationer för multipel skleros). www.mpa.se
2 Noseworthy J, Lucchinetti C, Rodriguez M, Weinshenker B. Multiple Sclerosis. N Engl J Med 2000;343:938-952
3 Compston A, Coles A. Multiple Sclerosis. Lancet 2002;359:1221-1231
4 Fredrikson S. När och hur bör man informera om diagnosen vid multipel skleros - etiska överväganden. Läkartidningen 1989;45:3909-3910
5 Poser CM, Paty DW, Scheinberg LC, McDonald WI, Davis FA, Eberd GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
6 McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin F, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127
7 Rutschmann, OT, McCrory DC, Matchar DB and the Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines. Immunization and MS - A summary of published evidence and recommendations. Neurology 2002;59:1837-1843
8 Confavreux C, Vukusic S. Natural history of multiple sclerosis: implications for counselling and therapy. Opin Neurol 2002;15: 257-266
9 Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S for the Vaccines in Multiple Sclerosis Study Group. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001;344:319-326
10 Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
11 The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology. 1995;45:1277-1285
12 Jacobs LD; Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294
13 PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504
14 The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276
15 Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49:290-297